Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.

This review examined why colorectal cancer often becomes resistant to standard treatments like chemotherapy. Researchers focused on cancer stem cells (CSCs), which are specialized cancer cells that can survive treatment and cause tumors to return or spread. These stem cells protect themselves by activating multiple survival pathways, repairing their own DNA damage, hiding from the immune system, and creating an environment that helps them thrive. The study found that CSCs use several specific molecular pathways including Wnt/β-catenin, Notch, and Hedgehog signaling to maintain their resistance to drugs.

The researchers explored new treatment approaches specifically targeting these cancer stem cells, including antibodies that attach to stem cell surfaces, drugs that block self-renewal signals, medications that change gene expression, and immunotherapies that help the immune system recognize cancer. Combining these newer therapies with traditional chemotherapy showed promise for overcoming resistance by attacking cancer through multiple mechanisms simultaneously. Nanotechnology drug delivery systems were also discussed as ways to get medications directly to tumors while reducing side effects.

For patients with colorectal cancer considering complementary therapies like acupuncture, this research highlights the complexity of treatment resistance. While acupuncture cannot target cancer stem cells directly, it may serve as supportive care to help manage chemotherapy side effects, reduce treatment-related nausea, improve quality of life, and support overall wellbeing during conventional cancer treatment. To explore acupuncture as part of an integrative cancer care plan, consult with a licensed acupuncturist experienced in oncology support.

This comprehensive review analyzes molecular mechanisms underlying cancer stem cell (CSC)-mediated drug resistance in colorectal carcinoma. CSCs maintain therapeutic resistance through activation of Wnt/β-catenin, Notch, Hedgehog, PI3K/Akt, and MAPK/ERK pathways, alongside epithelial-mesenchymal transition, enhanced DNA repair mechanisms, and PD-1/PD-L1-mediated immune evasion. The tumor microenvironment becomes a stemness-supportive, immunosuppressive niche promoting recurrence and metastasis. Emerging therapeutic strategies include monoclonal antibodies targeting CSC surface antigens, small-molecule pathway inhibitors, epigenetic reprogramming agents, and immune checkpoint blockade. Multi-drug regimens combining CSC-targeted therapies with conventional chemotherapy demonstrate synergistic efficacy. Nanotechnology-based delivery systems enhance bioavailability and tumor specificity while minimizing systemic toxicity. Clinical translation faces challenges including CSC heterogeneity, compensatory pathway activation, and lack of robust biomarkers. For acupuncture practitioners, understanding these resistance mechanisms informs patient education and positions acupuncture appropriately as chemotherapy-supportive care rather than primary oncologic intervention.